Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$1.25M$1.25M−58.4% vs Q3 2022 Net Income-$7.11M-$7.11MN/M vs Q3 2022 EPS Diluted-$0.04-$0.04N/M vs Q3 2022 Gross Profit$1,077,000−61.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,037,000N/M Free Cash Flowderived-$5,176,000N/M Margins · derivedGross margin86.4%−5.7 pt vs Q3 2022
Operating margin-538.1%−363.0 pt vs Q3 2022
Net margin-570.6%−368.2 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end